Breaking News

Xceleron, Kinetigen in Pharmacokinetic Pact

February 26, 2013

Aims to provide simpler, more robust early investigations

Xceleron has partnered with Kinetigen, a clinical pharmacology consulting firm specializing in pharmacokinetics, to offer drug developers solutions for robust and cost-effective investigations of Phase I drug pharmacokinetics. Kinetigen will provide its complex PK analyses and overall clinical pharmacology strategies and Xceleron will use its Accelerator Mass Spectrometry (AMS) to gain analytical insight across a broad range of asset classes and matrix types.
 
“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership with Kinetigen will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, chief executive officer of Xceleron.
 
“Our partnership with Xceleron is very synergistic,” said Dr. Geoffrey Banks, chief executive officer of Kinetigen.  “Matching Kinetigen’s PK expertise with Xceleron’s AMS technology is a ‘win-win’ situation for clients seeking more robust options for analysis and interpretation of Phase I PK data.”

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research